Dynamics of provirus load and lymphocyte subsets after interleukin 2 treatment in HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 15, Issue 2, 1999, Pages 97-103

  Zanussi, Stefania ^a   Simonelli, Cecilia ^a   Bortolin, Maria Teresa ^a   D'Andrea, Monica ^a   Comar, Manola ^b   Tirelli, Umberto ^a   Giacca, Mauro ^b   De Paoli, Paolo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; RANTES; RECOMBINANT INTERLEUKIN 2; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; PHENOTYPE; PRIORITY JOURNAL; PROVIRUS; VIREMIA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIDANOSINE; FEMALE; HIV; HUMANS; INTERLEUKIN-2; MALE; POLYMERASE CHAIN REACTION; PROVIRUSES; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; ZIDOVUDINE;

EID: 0033585448     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311529     Document Type: Article

References (37)

1. Emery S and Lane HC: Immune-based therapies in HIV infection: Recent developments. AIDS 1996;10:S159-S163.
2. Pantaleo G: How immune-based interventions can change HIV therapy. Nature Med 1997;3:483-490.
3. Schwartz DH, Skowron G, and Merigan T: Safety and effects of IL2 plus zidovudine in asymptomatic individuals infected with HIV. J Acquir Immune Defic Syndr 1991;4:11-23.
4. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, and Cohn ZA: Prolonged immunostimulatory effect of low-dose PEG IL2 in patients with HIV 1 infection. J Exp Med 1993;177:483-492.
5. Leef Jacobson E, Pilaro E, and Smith KA: Rational IL2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996;93: 10405-10410.
6. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J, Polis MA, Walker RE, Stevans R, Salzman NP, Metcalf JA, Masur H, and Lane C: Increased in CD4 T lymphocytes with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-575.
7. De Paoli P, Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Crepaldi C, Talamini R, Comar M, Giacca M, and Tirelli U: Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest 1997;100:2737-2743.
8. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, and Volberding PA: HIV viral load markers in clinical practice. Nature Med 1996;2:625-629.
9. Donovan RM, Dickover RE, Goldstein E, Huth RG, and Carlson JR: HIV-1 proviral copy number in blood mononuclear cells from AIDS patients on zidovudine therapy. J Acquir Immune Defic Syndr 1991;4:766-769.
10. Escaich S, Ritter J, Rougier P, Lepot D, Lamelin JP, Sepetjan M, and Trepo C: Relevance of the quantitative detection of HIV proviral sequences in PBMC of infected individuals. AIDS Res Hum Retroviruses 1992;8:1833-1837.
11. Luque F, Caruz A, Pineda JA, Torres Y, Larder B, and Leal M: Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. J Infect Dis 1994;169:267-273.
12. Tamalet C, Lafeuillade A, Fantini J, Poggi C, and Yahi N: Quantification of HIV-1 viral load in lymphoid and blood cells: Assessment during four-drug combination therapy. AIDS 1997;11:895-901.
13. Stevenson M, Stanwick TL, Dempsey MP, and Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990;9:1551-1560.
14. Bukrinsky MI, Stanwick TL, Dempsey MP, and Stevenson M: Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991;254:423-427.
15. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, and Siliciano RF: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (London) 1997;387:183-188.
16. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmwyer R, Gallant J, Markowitz M, Ho DD, Richman DD, and Siciliano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
17. Holter W, Rabson AN, Corsico CD, and Howard BH: Segment specific toxicity of transfected retroviral DNA. Exp Cell Res 1991;193:54-58.
18. Schnittman SM, Greenhouse JJ, Psallidopoulos MC, Baseler M, Salzman NP, Fauci AS, and Lane HC: Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med 1990;113:438-443.
19. Yerly S, Chamot E, Hirschel B, and Perrin LH: Quantitation of human immunodeficiency virus provirus and circulating virus: Relationship with immunologic parameters. J Infect Dis 1992;166:269-276.
20. Chevret S, Kirstetter M, Mariotti M, Lefrère F, Frottier J, and Lefrère JJ: Provirus copy number to predict disease progression in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:882-885.
21. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;4:1-19.
22. Simonelli C, Zanussi S, Comar M, De Paoli P, Giacca M, and Tirelli U: IL2 in combination with AZT + DDI is able to maintain high levels of CD4 and undetectable HIV-viremia. AIDS 1998;12:112-113.
23. Simonelli C, Zanussi S, Sandri S, Comar M, Lucienti A, Talamini R, Bortolin MT, Giacca M, De Paoli P, and Tirelli U: Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection. J Acquir Immune Defic Syndr Hum Retrovir, in press.
24. Giacca M, Zanussi S, Comar M, Simonelli C, Vaccher E, De Paoli P, and Tirelli U: Treatment of HIV infection with hydroxyurea: Virological and clinical evaluation. J Infect Dis 1996;174:204-209.
25. Comar M, Marzio G, D'Agaro P, and Giacca M: Quantitative dynamics of HIV-1 expression. AIDS Res Hum Retroviruses 1996; 12:117-126.
26. Comar M, Simonelli C, Zanussi S, De Paoli P, Vaccher E, Tirelli U, and Giacca M: Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection. J Clin Invest 1997;100:893-903.
27. Stevenson M: Molecular mechanisms for the regulation of HIV replication, persistence and latency. AIDS 1997;11:S25-S33.
28. Kinter AL, Poli G, Fox L, Hardy E, and Fauci AS: HIV replication in IL-2 stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995;154:2448-2459.
29. Patki AH, Quiñones-Mateu ME, Dorazio D, Yen-Lieberman B, Boom WH, Thomas EK, and Lederman MM: Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression. J Clin Invest 1996;98:616-621.
30. Wood R, Montoya JG, Kundu SM, Schwartz DH, and Merigan TC: Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: A phase I/II study. J Infect Dis 1993;167;519-525.
31. Rook AH, Masur H, Lane HC, Frederick W, Kasahara T, Macher AM, Dieu JY, Manischewitz JF, Jackson L, Fauci AS, and Quinnan GV: Interleukin-2 enhances the depressed natural killer and cytomegalovirus specific cytotoxic activities of lymphocytes obtained from patients with the acquired immunodeficiency syndrome. J Clin Invest 1983;72:398-403.
32. Unutmaz D, Pileri P, and Abrignani S: Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J Exp Med 1994;180:1159-1164.
33. Helbert MR, L'age-Stehr J, and Mitchison NA: Antigen presentation, loss of immunological memory and AIDS. Immunol Today 1993;14:340-344.
34. Woods TC, Roberts BD, Butera ST, and Folks TM: Loss of inducible virus in CD45RA naive cells after human immunodeficiency virus-1 entry accounts for preferential viral replication in CD45RO memory cells. Blood 1997;89:1635-1641.
35. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, and Fauci AS: Preferential infection of CD4 memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990;87:6058-6062.
36. Spina CA, Prince HE, and Richman DD: Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin Invest 1997;99:1774-1785.
37. Roederer M, Raju PA, Mitra DK, Herzenberg LA, and Herzenberg LA: HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. J Clin Invest 1997;99:1555-1564.